Melio, a LongeVC portfolio company, has received $3.5 million in funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its rapid diagnostic platform for bloodstream infections, including neonatal sepsis.
The diagnostic integrates molecular and microfluidic technologies to detect pathogens and drug resistance directly from blood samples in just three hours. This is a major improvement over current multi-day culture-based methods and could transform neonatal care by enabling faster, targeted treatments that save lives and reduce unnecessary antibiotic use.
Neonatal sepsis is one of the leading causes of mortality in newborns, and every hour of delayed treatment increases the risk of death. By addressing this urgent need, Melio’s platform fills a crucial gap in diagnostics, offering a way to improve outcomes for some of the most vulnerable patients.
For more on Melio’s work and its partnership with CARB-X, read the full announcement here.
The diagnostic integrates molecular and microfluidic technologies to detect pathogens and drug resistance directly from blood samples in just three hours. This is a major improvement over current multi-day culture-based methods and could transform neonatal care by enabling faster, targeted treatments that save lives and reduce unnecessary antibiotic use.
Neonatal sepsis is one of the leading causes of mortality in newborns, and every hour of delayed treatment increases the risk of death. By addressing this urgent need, Melio’s platform fills a crucial gap in diagnostics, offering a way to improve outcomes for some of the most vulnerable patients.
For more on Melio’s work and its partnership with CARB-X, read the full announcement here.